|
|
|
|
Gilead dips on analyst's patent concerns
shares dipped on Monday as a stock analyst said the Foster City-based company (NASDAQ: GILD) faces a steep patent cliff, beginning in 2014.Patents for the HIV drug Viread, flu treatment Tamiflu and hepatits B treatment Hepsera are among those that lose their...
|
|
|
Gilead dips on analyst's patent concerns
Gilead Sciences Inc.shares dipped on Monday as a stock analyst said the Foster City-based company (NASDAQ: GILD) faces a steep patent cliff, beginning in 2014. Patents for the HIV drug Viread, flu treatment Tamiflu and hepatits B treatment Hepsera are...
|
|
|
Gilead dips on analyst's patent concerns
shares dipped on Monday as a stock analyst said the Foster City-based company (NASDAQ: GILD) faces a steep patent cliff, beginning in 2014.Patents for the HIV drug Viread, flu treatment Tamiflu and hepatits B treatment Hepsera are among those that lose their...
|
|
|
Gilead dips on analyst's patent concerns
shares dipped on Monday as a stock analyst said the Foster City-based company (NASDAQ: GILD) faces a steep patent cliff, beginning in 2014.Patents for the HIV drug Viread, flu treatment Tamiflu and hepatits B treatment Hepsera are among those that lose their...
|
|
|
Gilead dips on analyst's patent concerns
shares dipped on Monday as a stock analyst said the Foster City-based company (NASDAQ: GILD) faces a steep patent cliff, beginning in 2014.Patents for the HIV drug Viread, flu treatment Tamiflu and hepatits B treatment Hepsera are among those that lose their...
|
|
|
Gilead downgraded on concerns about key patents
A Morgan Joseph analyst downgraded shares of Gilead Sciences Inc.Monday, saying the company does not have a way to make up the revenue it will lose when several of its top drugs go off-patent later this decade. Analyst Shiv Kapoor said Gilead gets about...
|
|
|
Gilead downgraded on concerns about key patents
NEW YORK -- A Morgan Joseph analyst downgraded shares of Gilead Sciences Inc.Monday, saying the company does not have a way to make up the revenue it will lose when several of its top drugs go off-patent later this decade. Analyst Shiv Kapoor said Gilead...
|
|
|
Gilead cut to 'Sell' as Morgan Joseph says company won't replace revenue from 5 key drugs
NEW YORK A Morgan Joseph analyst downgraded shares of Gilead Sciences Inc.Monday, saying the company does not have a way to make up the revenue it will lose when several of its top drugs go off-patent later this decade. Analyst Shiv Kapoor said Gilead gets...
|
|
|
Gilead downgraded on concerns about key patents
NEW YORK (AP) -- A Morgan Joseph analyst downgraded shares of Gilead Sciences Inc.Monday, saying the company does not have a way to make up the revenue it will lose when several of its top drugs go off-patent later this decade.Analyst Shiv Kapoor said Gilead...
|
|
|
Gilead downgraded on concerns about key patents
NEW YORK (AP) -- A Morgan Joseph analyst downgraded shares of Gilead Sciences Inc.Monday, saying the company does not have a way to make up the revenue it will lose when several of its top drugs go off-patent later this decade.Analyst Shiv Kapoor said Gilead...
|
|
|
Scientists find single-dose of drug cures visceral leishmaniasis
A study has shown that a single infusion of Gilead Sciences' drug AmBisome, known generically as iposomal amphotericin B, cured nearly all patients with visceral leishmaniasis, or kala-azar, a parasitic infection, Reuters reports.Spread by the sand fly...
|
|
|
Medical News: Scientists Find Single Dose Of Drug Cures Visceral Leishmaniasis
A study has shown that a single infusion of Gilead Sciences' drug AmBisome, known generically as iposomal amphotericin B, cured nearly all patients with visceral leishmaniasis, or kala-azar, a parasitic infection, Reuters reports.Medical News:...
|
|
|
Single dose cure for leishmaniasis
A single dose of AmBisome could help treat more patients with the deadly infection leishmaniasis, according to a new study.Researchers found a single dose of the drug, known as liposomal amphotericin B, cured nearly every case of the parasitic...
|
